Cargando…

Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure

The US FDA defines modified risk tobacco products (MRTPs) as products that aim to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products.  Establishing a product’s potential as an MRTP requires scientific substantiation including toxicity studies an...

Descripción completa

Detalles Bibliográficos
Autores principales: Boué, Stéphanie, Exner, Thomas, Ghosh, Samik, Belcastro, Vincenzo, Dokler, Joh, Page, David, Boda, Akash, Bonjour, Filipe, Hardy, Barry, Vanscheeuwijck, Patrick, Hoeng, Julia, Peitsch, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657032/
https://www.ncbi.nlm.nih.gov/pubmed/29123642
http://dx.doi.org/10.12688/f1000research.10493.2
_version_ 1783273806531395584
author Boué, Stéphanie
Exner, Thomas
Ghosh, Samik
Belcastro, Vincenzo
Dokler, Joh
Page, David
Boda, Akash
Bonjour, Filipe
Hardy, Barry
Vanscheeuwijck, Patrick
Hoeng, Julia
Peitsch, Manuel
author_facet Boué, Stéphanie
Exner, Thomas
Ghosh, Samik
Belcastro, Vincenzo
Dokler, Joh
Page, David
Boda, Akash
Bonjour, Filipe
Hardy, Barry
Vanscheeuwijck, Patrick
Hoeng, Julia
Peitsch, Manuel
author_sort Boué, Stéphanie
collection PubMed
description The US FDA defines modified risk tobacco products (MRTPs) as products that aim to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products.  Establishing a product’s potential as an MRTP requires scientific substantiation including toxicity studies and measures of disease risk relative to those of cigarette smoking.  Best practices encourage verification of the data from such studies through sharing and open standards. Building on the experience gained from the OpenTox project, a proof-of-concept database and website ( INTERVALS) has been developed to share results from both in vivo inhalation studies and in vitro studies conducted by Philip Morris International R&D to assess candidate MRTPs. As datasets are often generated by diverse methods and standards, they need to be traceable, curated, and the methods used well described so that knowledge can be gained using data science principles and tools. The data-management framework described here accounts for the latest standards of data sharing and research reproducibility. Curated data and methods descriptions have been prepared in ISA-Tab format and stored in a database accessible via a search portal on the INTERVALS website. The portal allows users to browse the data by study or mechanism (e.g., inflammation, oxidative stress) and obtain information relevant to study design, methods, and the most important results. Given the successful development of the initial infrastructure, the goal is to grow this initiative and establish a public repository for 21 (st)-century preclinical systems toxicology MRTP assessment data and results that supports open data principles.
format Online
Article
Text
id pubmed-5657032
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-56570322017-11-08 Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure Boué, Stéphanie Exner, Thomas Ghosh, Samik Belcastro, Vincenzo Dokler, Joh Page, David Boda, Akash Bonjour, Filipe Hardy, Barry Vanscheeuwijck, Patrick Hoeng, Julia Peitsch, Manuel F1000Res Method Article The US FDA defines modified risk tobacco products (MRTPs) as products that aim to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products.  Establishing a product’s potential as an MRTP requires scientific substantiation including toxicity studies and measures of disease risk relative to those of cigarette smoking.  Best practices encourage verification of the data from such studies through sharing and open standards. Building on the experience gained from the OpenTox project, a proof-of-concept database and website ( INTERVALS) has been developed to share results from both in vivo inhalation studies and in vitro studies conducted by Philip Morris International R&D to assess candidate MRTPs. As datasets are often generated by diverse methods and standards, they need to be traceable, curated, and the methods used well described so that knowledge can be gained using data science principles and tools. The data-management framework described here accounts for the latest standards of data sharing and research reproducibility. Curated data and methods descriptions have been prepared in ISA-Tab format and stored in a database accessible via a search portal on the INTERVALS website. The portal allows users to browse the data by study or mechanism (e.g., inflammation, oxidative stress) and obtain information relevant to study design, methods, and the most important results. Given the successful development of the initial infrastructure, the goal is to grow this initiative and establish a public repository for 21 (st)-century preclinical systems toxicology MRTP assessment data and results that supports open data principles. F1000Research 2017-09-05 /pmc/articles/PMC5657032/ /pubmed/29123642 http://dx.doi.org/10.12688/f1000research.10493.2 Text en Copyright: © 2017 Boué S et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Method Article
Boué, Stéphanie
Exner, Thomas
Ghosh, Samik
Belcastro, Vincenzo
Dokler, Joh
Page, David
Boda, Akash
Bonjour, Filipe
Hardy, Barry
Vanscheeuwijck, Patrick
Hoeng, Julia
Peitsch, Manuel
Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
title Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
title_full Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
title_fullStr Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
title_full_unstemmed Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
title_short Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
title_sort supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure
topic Method Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657032/
https://www.ncbi.nlm.nih.gov/pubmed/29123642
http://dx.doi.org/10.12688/f1000research.10493.2
work_keys_str_mv AT bouestephanie supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT exnerthomas supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT ghoshsamik supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT belcastrovincenzo supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT doklerjoh supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT pagedavid supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT bodaakash supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT bonjourfilipe supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT hardybarry supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT vanscheeuwijckpatrick supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT hoengjulia supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure
AT peitschmanuel supportingevidencebasedanalysisformodifiedrisktobaccoproductsthroughatoxicologydatasharinginfrastructure